Skip to content
US Proposes Restrictions on Chinese Biotech Investments

US Proposes Restrictions on Chinese Biotech Investments

First seen 23 Oct 2026, 23:13 UTC • •

Article Content

Browse articles
ThreatCluster AI
ThreatCluster •October 24, 2026 at 23:13 UTC
  • •The US Treasury's proposed rule restricts investments in Chinese biotech under the COINS Act.
  • •The rule prohibits financial transactions with Chinese biotech companies, affecting future collaborations.
  • •US drugmakers can still buy rights to Chinese-developed medicines despite the new restrictions.

On October 23, 2026, the US Treasury Department proposed a rule under the COINS Act that would impose significant restrictions on US investments in the Chinese biotech sector. This rule adds biotechnology to a list of industries deemed sensitive to national security, which already includes semiconductors and AI. The proposal prohibits US companies from engaging in financial transactions with Chinese biotech firms or manufacturers of related equipment. While American drugmakers can still acquire rights to medicines developed in China, the new restrictions are expected to dramatically impact ongoing and future partnerships. The biotech industry, which has seen a surge of deals between the US and China in recent years, is now bracing for a lobbying effort to influence the rule's final form. The announcement has sparked discussions about the potential ramifications for innovation and collaboration in the biotech field.

Start a free Starter trial for enhanced analysis

Ask AI about this cluster

Updated 22d ago How this analysis works

Timeline

2026-10-23
US Treasury proposes biotech investment restrictions
The Treasury Department announced a rule under the COINS Act to restrict US investments in Chinese biotech, impacting future collaborations.
Endpoints.News
2026-10-23
Industry reacts to proposed rule
Biotech industry stakeholders began discussions on lobbying efforts to influence the proposed restrictions following the announcement.
Statnews

More articles in this cluster (4)

Common questions

What does the COINS Act entail?
The COINS Act restricts US investments in sensitive technologies, including biotechnology, to protect national security.
How will this affect US-China biotech partnerships?
The proposed restrictions are expected to significantly limit future collaborations and financial transactions between US and Chinese biotech firms.
What can biotech companies do in response?
Biotech companies may engage in lobbying efforts to influence the final rule and mitigate its impact on their operations.